quantisnow
FeedTopReportsPricing
⌘K
Live feed
19:18:56·940d
INSIDERFiling
Reata Pharmaceuticals Inc. logo

Mcgaughy R Kent Jr returned 2,926,776 shares to the company, closing all direct ownership in the company (SEC Form 4)

RETA· Reata Pharmaceuticals Inc.
Health Care
Original source

Companies

  • RETA
    Reata Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Jul 6UpdateTD Cowen$140.00
  • Jun 12UpdateSVB Securities$115.00
  • Oct 19UpdateGuggenheim$75.00
  • Mar 24UpdateGoldman$91.00
  • Mar 1UpdateGoldman Sachs$34.00
  • Dec 9UpdateGoldman Sachs$39.00

Related

  • NEWS846d
    Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
  • SEC930d
    SEC Form 15-12G filed by Reata Pharmaceuticals Inc.
  • NEWS931d
    An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8
  • 13D/G938d
    SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)
  • INSIDER938d
    Desai Antal Rohit returned 2,928,368 shares to the company (SEC Form 4)
  • 13D/G938d
    SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)
  • SEC940d
    Reata Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update
  • 13D/G940d
    SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022